Pedro Reche López

Suggest Changes
Learn More
PURPOSE The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study to assess the efficacy and toxicity of edatrexate, a folate antagonist, in 35 patients with(More)